91
Views
6
CrossRef citations to date
0
Altmetric
Review

Neurokinin-3 receptor antagonists in schizophrenia

&
Pages 925-937 | Published online: 21 Jun 2006
 

Abstract

Two neurokinin-3 receptor (NK3r) antagonists, osanetant and talnetant, have recently shown positive results in clinical trials for schizophrenia. Following these disclosures, research has accelerated significantly. This review focuses on progress for NK3r antagonists since 2004, primarily from the patent literature. The emphasis here is on NK3r antagonists as treatments for schizophrenia. In addition, antagonists of NK3r that have efficacy at NK1r and/or NK2r have also been explored as antipsychotics or as treatments for other psychiatric disorders and these will be included in this review.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.